- 2023 Annual Meeting
- The PCORI Strategic Plan
- Clinical Effectiveness and Decision Science
- Dissemination and Implementation
- Evaluation and Analysis
- Healthcare Delivery and Disparities Research
- PCOR Infrastructure & Innovation
- Our Vision & Mission
- Financial Statements and Reports
- The PCORI Strategic Plan
- Board of Governors
- Methodology Committee
- Authorizing Law
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
Past Opportunities to Provide Input
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
- Past Opportunities to Provide Input
Washington, D.C. (March 25, 2014) -- The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved 13 people as members of PCORI’s new Advisory Panel on Rare Disease. It is one of two new advisory panels for which the Board approved members at its meeting today; the other focuses on clinical trials.
The diverse group of panelists will apply their experience and expertise to advising PCORI on its research priorities in the area of rare disease, as well as on engaging with the rare disease research community. Rare diseases are defined in the United States as conditions that occur in fewer than 200,000 people.
"Although they're called rare, these are conditions that collectively affect millions of Americans and their families and they merit our attention as we seek to support comparative effectiveness research on patients' most pressing unanswered questions," said Bryan Luce, PhD, MBA, PCORI's Chief Science Officer. "We're pleased that so many qualified individuals wanted to lend their experience and deep knowledge to ensure that we support high-quality research on rare conditions and we'll benefit greatly from the insights of this stellar group of individuals."
The new panelists represent a range of stakeholder groups and perspectives, including people with rare diseases, family caregivers, clinicians, drug and device makers, and researchers, among others. More than a third represent patients and patient advocates. A list of the new panelists, with brief biographies and conflict of interest disclosures, is available on PCORI's website.
The panel members and three alternates were selected from 129 applicants. PCORI staff thoroughly evaluated every candidate's personal experience and qualifications in the area of rare disease as well as their ability to contribute to the panel’s advisory tasks and responsibilities. More information about PCORI's process for reviewing and recommending advisory panel nominees is available on its website.
The panel's composition will enable it to carry out a variety of tasks, including providing input on the research needs of the rare disease community and advising on strategies for disseminating study findings. However, given that the National Institutes of Health lists more than 6,800 rare conditions, the panel will assist PCORI in identifying experts to serve on ad hoc advisory panels as needed to consider research issues related to particular conditions. More details about the panel's responsibilities and activities can be found in its charter.
PCORI's authorizing legislation allows it to appoint permanent or ad hoc advisory panels to assist it in identifying research priorities and establishing its research agenda and specifically called on the institute to establish an expert panel on rare disease. While they are not policy-making groups, their advice and recommendations inform the work and decisions of PCORI's staff, Board and committees.
The panel members have been notified of their appointment to the panel and are expected to respond to their invitations today. If needed, alternate members will be selected from the list also approved by the Board today. The Advisory Panel on Rare Disease will convene for its first meeting on Wednesday, April 30, in Washington, D.C.
The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed health care decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work.
The Patient-Centered Outcomes Research Institute (PCORI) is an independent nonprofit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions. PCORI is committed to continually seeking input from a broad range of stakeholders to guide its work.
Recent News Releases
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.